| Target Validation Information | |||||
|---|---|---|---|---|---|
| TTD ID | T64213 | ||||
| Target Name | Transient receptor potential cation channel V4 (TRPV4) | ||||
| Type of Target |
Clinical trial |
||||
| Drug Potency against Target | Drug Info | IC50 = 110 nM | [2] | ||
| 4-Pyridin-2-yl-piperazine-1-carboxylic acid amide | Drug Info | IC50 = 30 nM | [3] | ||
| 5'-iodoresiniferatoxin | Drug Info | IC50 = 4000 nM | [3] | ||
| CAPSAZEPINE | Drug Info | IC50 = 600 nM | [1] | ||
| Pyrrolidin-1-yl-thiourea | Drug Info | IC50 = 3000 nM | [3] | ||
| SC-0030 | Drug Info | IC50 = 37 nM | [2] | ||
| References | |||||
| REF 1 | Chain-branched acyclic phenethylthiocarbamates as vanilloid receptor antagonists. Bioorg Med Chem Lett. 2003 May 5;13(9):1549-52. | ||||
| REF 2 | Novel non-vanilloid VR1 antagonist of high analgesic effects and its structural requirement for VR1 antagonistic effects. Bioorg Med Chem Lett. 2003 Dec 15;13(24):4389-93. | ||||
| REF 3 | N-4-methansulfonamidobenzyl-N'-2-substituted-4-tert-butyl-benzyl thioureas as potent vanilloid receptor antagonistic ligands. Bioorg Med Chem Lett. 2004 Apr 5;14(7):1693-6. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.